Louisiana Medicaid Pharmacy Coverage Update for COVID Treatment Nirmatrelvir/Ritonavir (Paxlovid)
Date: 09/05/24
Effective October 1, 2024, the Louisiana Medicaid Pharmacy Program will assess copayments for the COVID treatment nirmatrelvir/ritonavir (Paxlovid).
Due to the end of the Public Health Emergency (PHE) for COVID-19, declared under Section 319 of the Public Health Service Act, the Pharmacy Program will assess copayments for the COVID treatment nirmatrelvir/ritonavir (Paxlovid).
This reinstatement of copayment does not apply to recipients who are copayment exempt.
If you have questions about pharmacy claims billing, you may contact the Medicaid Pharmacy Benefit Manager, Magellan, at 1-800-424-1664.